EB140: Statement of India on the Report of the United Nations High-Level Panel on Access to Medicines

Posted on by Thiru

On the morning of Monday, 23 January 2017, India delivered the following intervention at the 140th session of the World Health Organization’s Executive Board requesting the “explicit inclusion” of the United Nations Secretary-General’s High-Level Panel Report in the “provisional agenda of the EB140 as a separate agenda item under item 8.”

In making the case for the inclusion of the UN HLP in the WHO’s Executive Board deliberations, India articulate the following:

Continue Reading →

Spinraza: KEI asks DHHS Office of the Inspector General (OIG) to investigate a failure to disclose federal funding in patents

Posted on by James Love

KEI has asked the DHHS Office of Inspector General (OIG) to investigate a failure to disclose federal funding of patents on nusinersen, a drug developed by Ionis Pharmaceuticals (formerly known as Isis Pharmacetuicals) with BioGen, and sold under the trade name Spinraza.

A copy of the 22 page letter to OIG is available here.

Continue Reading →

SCP25: Closing Statement of the Republic of South Africa

Posted on by Thiru

On Thursday, 15 December 2016, South Africa delivered this poignant, closing statement at WIPO’s Standing Committee on the Law of Patents (SCP). Negotiations broke down on the issue of future work, as the European Union and Group B refused to permit discussions of the Report of the UN Secretary-General’s High-Level Panel on Access to Medicines at future sessions of the SCP.

According to the WIPO website,

Continue Reading →

2016: KEI comments to NIST on Bayh-Dole Act Regulations

Posted on by James Love

In November, NIST proposed to amend the regulations implementing the Bayh-Dole Act, 35 U.S.C. 200 et seq., which concerns intellectual property arising from federally-funded research, including 37 CFR sections 401 and 404. There were 15 comments, including a letter from KEI on December 9, 2016. EFF also provided comments. The other 13 comments to NIST were from Universities, associations or individuals taking the side of right-holders.

The KEI comments are available here.

Continue Reading →

Uncategorized